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ABSTRACT
Introduction: Neovascular age-related macular
degeneration (nAMD) is a chronic eye condition
that causes severe deterioration of vision and
ultimately blindness. Two vascular endothelial
growth factor inhibitors are approved for nAMD
treatment in Europe: ranibizumab and afliber-
cept. The European license for ranibizumab was
updated with an individualized ‘‘treat and
extend’’ (T&E) regimen, which involves more
proactive treatment based on changes in best
corrected visual acuity (BCVA) and/or anatom-
ical outcomes. The aim of this publication is to
compare the efficacy of the ranibizumab T&E
regimen with other approved dosing regimens
for nAMD on the basis of outcomes identified
from a systematic review and subsequent NMA.
Methods: Following a systematic search of
publications, to identify relevant studies, a
repeated-measures network meta-analysis
(NMA) was performed to estimate the relative
effectiveness of ranibizumab T&E versus
approved dosing regimens of ranibizumab and
aflibercept. The analysis focused on licensed
treatment regimens for nAMD. We examined
mean change from baseline in BCVA on the
Early Treatment Diabetic Retinopathy Study
(ETDRS) chart.
Results: The systematic literature review iden-
tified 22,949 records, of which 23 studies were
included in the NMA. At 12 months, the rani-
bizumab T&E dosing regimen vs ranibizumab
pro re nata (PRN) was associated with small
differences in change in BCVA, between 1.86
letter gain at 12 months and 2.35 letter gain at
24 months. A similar difference was observed in
the aflibercept dosing regimen versus ranibizu-
mab T&E ; 1.94 letter gain at 12 months and
3.31 letter gain at 24 months. All doses of
ranibizumab and aflibercept showed similar
effectiveness, and the differences between
treatment options were not significant.
Conclusion: This study used novel
repeated-measures NMA to synthesize efficacy
results when treatment effects were reported
at multiple follow-up times. This
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INTRODUCTION
Neovascular age-related macular degeneration
(nAMD) is a leading cause of vision loss globally
[1, 2]. Studies have estimated that 8.7% of the
worldwide population has AMD; the projected
number of people worldwide with the disease is
196million in2020,which isprojected to increase
to 288 million by 2040 [3]. In 2013, over 338,000
individuals in the UK were affected by nAMD,
with 50,000 cases resulting in blindness [4–6].
There have been significant advances in the
management of nAMD since the approval of
anti-VEGF therapies, and patients now have
effective treatment options that can limit the
progression to blindness [7–9]. Anti-VEGF
injections aim to inhibit the growth of new,
abnormal blood vessels. Two anti-VEGF thera-
pies that target VEGF-A have been approved for
intraocular use in nAMD cases by the European
Medicines Association (EMA) for the treatment
of nAMD [10, 11]: ranibizumab (Lucentis;
Novartis Pharma AG, Basel, Switzerland) [10]
and aflibercept (Eylea; Bayer Pharma AG, Ber-
lin, Germany) [11].
With two approved anti-VEGF treatments
and multiple dosing regimens reported in the
UK clinical practice, decisions on the optimal
treatment regimen are increasingly difficult. In
September 2014, the license for ranibizumab
was updated to include a new ‘‘treat and
extend’’ (T&E) regimen, in which patients are
treated monthly until maximum visual acuity
(BCVA) is achieved and/or there are no signs of
disease activity, and then treatment intervals
are extended in a stepwise manner of no more
than 2 weeks at a time until signs of disease
activity or visual impairment recur [10]. The
effectiveness of treating nAMD patients with
ranibizumab according to the T&E regimen has
been demonstrated in two randomized con-
trolled trials (RCTs) [12–14]. However, the main
comparisons have been to unlicensed treatment
and not to other approved dosing regimens.
Thus indirect comparisons are needed to eval-
uate the relative effects of different treatments
over time and to inform decision-makers on the
optimal treatment choice [15–17].
Network meta-analysis (NMA) takes into
account both direct and indirect evidence. In
addition to the complexity created by changing
dosing regimens, the trials that inform this
comparison have varying lengths of follow-up
and report the outcomeof interest (mean change
in BCVA) at different time intervals. In such a
situation, it is important to utilize all available
information for all the time points reported in
the trials to be able to estimate accurately the
relative treatment effectiveness. For these pur-
poses, a repeated-measures NMAmodel was used
to model the relative treatment effectiveness.
In clinical practice in the UK, both ranibi-
zumab and aflibercept are recommended as
first-line agents for the treatment of nAMD and
the decision to use either agent is left to the
treating physician [18]. The purpose of this
publication is to compare the efficacy of the
ranibizumab T&E regimen with other approved
dosing regimens for nAMD on the basis of out-
comes identified from a systematic review and
subsequent NMA.
METHODS
The NMA reported in this manuscript is an
update of a review and NMA originally con-
ducted in 2013 to compare the efficacy of a
range of interventions for the treatment of
nAMD. Results of the comparisons of ranibizu-
mab T&E versus approved dosing regimens of
ranibizumab and aflibercept are presented in
this manuscript.
612 Adv Ther (2017) 34:611–619
Eligibility Criteria
Trials were eligible for inclusion in the sys-
tematic review if they assessed adult patients
with nAMD and all relevant synonyms (e.g.,
exudative macular degeneration, choroidal
neovascularization, AMD, age-related macular
degeneration (ARMD)). Trials of mixed popu-
lations were eligible if the results for patients
with nAMD were reported separately.
Prospective RCTs, which assessed BCVA and
compared any of the following interventions,
were eligible for inclusion in the NMA: rani-
bizumab, unlicensed bevacizumab, aflibercept,
photodynamic therapy, placebo, sham, or best
supportive care.
Search Strategy
For the update to the systematic review, we
searched 18 databases, websites, trial registries
and three conference websites between Febru-
ary and March 2016. The search strategy for
MEDLINE is shown in Supplemental Fig. 1
(Fig. S1) and the other searches are available on
request. This search strategy was originally
developed in 2013, and then updated for this
analysis taking into account relevant recent
changes in indexing [19, 20]. The searches were
not limited by date, language, or document
type. The information sources searched are
shown in Supplemental Table 1 (Table S1).
Search results were downloaded into Endnote
and de-duplicated against each other and
against the results of the original review.
Study Selection
The records were screened for relevance to the
NMA on the basis of information in the title
and abstract, by two independent reviewers.
Any disagreements were discussed with a third
reviewer. Full-text documents of all potentially
relevant records were obtained and evaluated in
detail against the eligibility criteria for partici-
pants, interventions, comparators, outcomes,
and study design. Studies that were excluded
following full-text review are reported in
Appendix 1 along with a reason for exclusion.
Data Extraction and Quality Assessment
Data extraction and quality assessment were
carried out by two reviewers independently
with discrepancies resolved by a third reviewer.
Data were extracted from all relevant trials in
relation to the trial design and methodology,
patient characteristics, details of the interven-
tion and treatment regimens, and data on
change in BCVA. Data were extracted at all time
points reported for each trial. Study risk of bias
was assessed according to the NICE STA guid-
ance for assessing the quality of RCTs [21].
Feasibility Assessment
NMA guidelines require studies in the network
to be sufficiently similar to facilitate a reliable
comparison. We used the guidance produced by
the Australian Pharmaceutical Benefits Advisory
Committee (PBAC) [22] on best practice for the
conduct of indirect and mixed treatment com-
parisons to guide this assessment. The feasibility
assessment evaluated the similarity of the trials
in relation to the methods employed in the
trials, participant populations, similarity of
treatments, and similarity of outcome
measures.
Network Meta-Analysis
A list of unique dosing regimens was generated
describing each of the treatments identified in
the literature review (Table S7) and a network
was constructed. Dakin et al. and Ding and Fu
NMAmodels were used to analyze the data at all
time points [23, 24] up to months 12 and 24.
This NMA framework allows for repeated mea-
surements of a continuous endpoint showing
random and systematic variation (without
specifying any particular relationship between
treatment effects and time) [23]. The model by
Ding and Fu assumes that the relationship of
the mean relative treatment effect with time
follows a parametric model [24]. Both fixed and
random effects models were fitted to the
1–24 months network using WinBugs. The
model with the minimum deviance informa-
tion criterion (DIC) was chosen.
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Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
RESULTS
Identification and Selection of Studies
The searches identified 22,949 records (Fig. 1).
After de-duplication against each other and
against the search results of the original review
[19, 20], 5587 recordswere assessed for relevance.
Thirty-four documents, reporting data for 14
trials, were identified from the update search as
eligible for inclusion in the NMA. Twenty-one of
these documents reported data for six trials,
which had already been identified in the previ-
ousNMA [19]. For this analysis, the remaining 13
documents reported data for eight new trials to
be considered for inclusion, ofwhich four studies
ultimately contributed to the comparisons of
interest to this network (Table S2). A total of 25
trials (21 from the original review and two from
the update search) were considered in the feasi-
bility assessment. A preferred reporting items for
systematic reviews and meta-analyses (PRISMA)
flow diagram showing the study selection pro-
cess is presented in Fig. 1.
Network Development
Feasible networks were identified for analyzing
mean changes in BCVA, which differed
depending on the time point. A number of
potential sources of heterogeneity were identi-
fied in the feasibility assessment of the 25 can-
didate trials: in particular, the potential for
heterogeneity due to differences in the methods
used, differences in the interventions used
(primarily with respect to the criteria used for
assessing retreatment), and differences in the
timing of reporting. However, following dis-
cussions with clinicians, it was decided that
these differences would be acknowledged but all
the studies would remain in the network.
Following an assessment of the available
data, two trials, DETAIL [25] and Moon et al.
[26], provided insufficient data to be included
in the final analysis. Therefore, data from 23
trials were included in the NMA (Fig. S2,
Tables S3–S6).
Results of the NMA
Treatment Differences at 12 and 24 Months
The randomeffectsmodel fit the data better than
the fixed effects model. The functional form
assumed byDing and Fu [24] to describe the time
component in the treatment effects fit the data
well, and better than the models described by
Dakin et al. [23]. The frequency of treatment
varied over time and therefore differentnetworks
were applied depending on the time point. All of
the 23 candidate trials reported data on BCVA at
one time point, but the frequency and duration
varied across the trials (Table S3). Table S7 pre-
sents the assumptions regarding the equivalence
of treatment regimens at 0–12 months. After
12 months all the treatment regimens in the
analysis were different, and hence no assump-
tions were necessary for the 24 month analysis.
In general, ranibizumab T&E resulted in
similar changes in BCVA compared to other
treatment regimens. Compared to aflibercept,
ranibizumab T&E was associated with an incre-
mental letter gain from baseline of 1.94 [95%
credible interval (CrI) -7.52 to 3.52] at
12 months and 3.31 (95% CrI -9.23 to 2.66)
letter gain at 24 months. The relative treatment
effectiveness of ranibizumab T&E was 1.86 (95%
CrI -7.38 to 3.61) letter gain at 12 months and
2.35 (95% CrI -7.82 to 3.19) letter gain at
24 months (Table 1) compared to ranibizumab
0.5 mg 39monthly, then as needed. A forest
plot comparing ranibizumab T&E with other
approved treatment strategies is shown in Fig. 2.
DISCUSSION
There is limited availability of head-to-head
randomized trial data on the comparative
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Fig. 1 Record selection process
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efficacy of different treatment regimens of
ranibizumab for the treatment of nAMD; this
analysis summarizes the available RCT evidence
for the effectiveness of the ranibizumab T&E
regimen. The results of the analysis show rani-
bizumab T&E to be an effective treatment regi-
men for nAMD. Ranibizumab T&E showed
minor increase in change in BCVA at 12 and
24 months compared to other licensed
treatments.
These estimates are based on evidence from
only two T&E RCTs, of which only one
informed the primary comparisons, and are
subject to a considerable degree of uncertainty
due to few data points. It is possible that the
observed outcome may change if estimates from
ranibizumab T&E were based on a larger num-
ber of clinical trials. Until additional evidence is
generated, this analysis provides insight on the
treatment effects of ranibizumab T&E in com-
parison to other approved treatment regimens
for healthcare decision-makers, as ranibizumab
T&E is increasingly implemented in UK clinical
practice. Furthermore, these results may be rel-
evant in settings outside of the UK where the
same approved anti-VEGF therapies are used in
the clinic.
The principal strength of this study is that it
accounts for the time structure in the data while
comparing treatments, thus increasing the pre-
cision of the treatment estimates. Traditionally,
the meta-analysis of trials with repeated mea-
sures was based on separate meta-analysis at
each relevant time point, or analysis at the final
time point of each trial. Such analysis would
have not utilized all the available trial data from
the different dosing regimens of interest at dif-
ferent time points; therefore, the estimates of
the relative treatment effectiveness would have
been less accurate.
Recently, several models for NMA of repe-
ated measures have been presented [24]. The
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NMA was undertaken using the most robust
methodology for NMA of repeated measures,
providing accurate estimates of the effects of
ranibizumab T&E in the absence of head-to-
head RCT data. Moreover, the Ding and Fu
model proposes a parametric model for the
response time of each treatment and can be
used to extrapolate the data at unobserved time
points. Therefore, NMA of repeated measures
should be explored more systematically in
appropriate future nAMD studies, as it allows
for an evaluation of the treatment effects over
time and overcomes some of the limitations of
standard NMA. The concept of a single full
network, as used in standard NMA, can be
somewhat misleading, as the full network
changes over time reflecting changes in indi-
vidual dosages. In such a situation, using NMA
of repeated measures could offer a greater
advantage in terms of obtaining more precise
estimates at specific time points.
NMA is subject to the same limitations as
pairwise meta-analysis [27], mainly related to
the quality of the individual studies and publi-
cation biases. Assessments of the risk of bias of
the included trials showed there to be signifi-
cant variability in the quality of the included
studies, with a number of the studies included
in our analysis failing to take appropriate steps
to minimize bias. While it is difficult to assess
formally the impact of including these within
the context of the NMA analysis, there is the
potential that the estimates generated from our
analysis are subject to bias as a result of the
inclusion of these studies.
As described above, our analysis is based on
an extensive search of the literature. Although
we identified several studies, the large number
of dosing regimens in the network means that
the network analyzed is relatively sparse, giving
the estimates considerable uncertainty. Another
limitation of the current analysis is that
observable heterogeneity based on baseline
BCVA has not been addressed. It has been
demonstrated in previous studies that a signifi-
cant association exists between baseline BCVA
and subsequent changes in BCVA following
treatment [28]. It was therefore proposed within
the current analysis to utilize meta-regression
techniques to adjust estimates for baseline
BCVA. Our study was only able to use aggregate
information on baseline BCVA, because indi-
vidual patient data from each of the trials were
unavailable. Actual treatment effectiveness may
therefore vary according to a patient’s BCVA in
a way that we were not able to demonstrate in
this analysis. NMA of repeated measures pro-
vides a clear advantage over standard NMA,
when the outcomes of interest across different
trials are not reported at the same time points.
Despite these limitations, our results show that
Fig. 2 Forest plots present the median treatment differ-
ence and 95% CrIs of rainbizumab T&E versus other
approved treatment regimens at a 12 months and b at
24 months
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ranibizumab T&E is similarly effective to other
approved treatment regimens of nAMD.
CONCLUSION
This study has shown the comparative effec-
tiveness of ranibizumab T&E with other
approved treatment regimens for nAMD. NMA
of repeated measures provides a clear advantage
over standard NMA, when the outcomes of
interest across different trials are not reported at
the same time points.
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